<DOC>
	<DOCNO>NCT00066443</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy epirubicin docetaxel use different way stop tumor cell divide stop grow die . Colony-stimulating factor pegfilgrastim may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Phase I/II trial study effectiveness combine epirubicin docetaxel pegfilgrastim treat woman locally advance inflammatory breast cancer .</brief_summary>
	<brief_title>Epirubicin , Docetaxel , Pegfilgrastim Treating Women With Locally Advanced Inflammatory Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose recommend phase II dose docetaxel epirubicin give pegfilgrastim woman locally advance inflammatory breast cancer . ( Phase I , group 1 close accrual 9/13/04 Phase II , group 1 close accrual 5/10/06 ) - Determine toxicity regimen patient . - Determine clinical pathological response rate duration response patient treat regimen . - Determine drug sensitivity resistance patient treat regimen . - Determine prognostic predictive marker patient treat regimen . OUTLINE : This nonrandomized , multicenter , dose-escalation study docetaxel epirubicin . - Phase I : Group 1 ( 21-day regimen ) ( close accrual 09/13/04 ) : Patients receive epirubicin IV 15 minute docetaxel IV 60 minute day 1 pegfilgrastim subcutaneously day 2 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients objective response 6 course may receive additional therapy discretion physician . Group 2 ( 14-day regimen ) : Patients receive epirubicin IV 15 minute docetaxel IV 60 minute day 1 pegfilgrastim subcutaneously day 2 . Treatment repeat every 14 day 8 course absence disease progression unacceptable toxicity . Patients objective response 8 course may receive additional therapy discretion physician . Cohorts 3-6 patient receive escalate dos epirubicin docetaxel maximum tolerate dose ( MTD ) determine . The MTD define dose 2 3 2 6 patient experience dose-limiting toxicity . - Phase II : Group 1 ( 21-day regimen ) ( close accrual 5/10/06 ) : Patients receive treatment phase I epirubicin docetaxel recommended Phase II dose . Group 2 ( 14-day regimen ) : Patients receive treatment phase I epirubicin docetaxel recommended Phase II dose . Patients follow 1 month , every 3 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : Approximately 90 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm invasive adenocarcinoma breast , meet follow criterion : T4 , NX , M0 Any T , N2N3 , M0 Inflammatory breast cancer ( redness least onethird breast ) , M0 No evidence metastatic disease chest xray , abdominal ultrasound CT scan bone scan Diagnosed within past 8 week Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 16 Sex Female Menopausal status Not specify Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute granulocyte count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic Bilirubin less upper limit normal ( ULN ) Must meet criterion 1 follow : ALT AST great 1.5 time ULN AND alkaline phosphatase great 2.5 time ULN ALT AST normal AND alkaline phosphatase great 5 time ULN Renal Creatinine great 1.5 time ULN Cardiovascular Resting LVEF normal MUGA echocardiogram No congestive heart failure No angina pectoris No myocardial infarction within past year No uncontrolled hypertension No uncontrolled arrhythmias Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception No malignancy within past 5 year except adequately treat nonmelanoma skin cancer curatively treat carcinoma situ cervix No symptomatic peripheral neuropathy grade 2 great No active infection No history significant neurological psychiatric disorder , include dementia seizures No peptic ulcer No unstable diabetes mellitus No contraindication dexamethasone No known sensitivity E. coliderived polyethylene glycol product Willing undergo core biopsy prior registration core biopsy 2 timepoints study Geographically accessible treatment followup PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy breast cancer Chemotherapy No prior chemotherapy breast cancer Endocrine therapy No prior hormonal therapy breast cancer No concurrent corticosteroid except premedication hypersensitivity reaction No concurrent oral contraception Radiotherapy No prior radiotherapy breast cancer Surgery No prior surgery breast cancer biopsy Other No prior systemic therapy breast cancer No concurrent investigational drug anticancer treatment No concurrent preventative IV antibiotic</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
</DOC>